Diagnosis and treatment of chronic cerebral ischemia. DIAMANT study results
https://doi.org/10.21518/2079-701X-2018-9-8-12
Abstract
The diagnosis of chronic cerebral ischemia (CHI) is based on the presence of vascular cognitive disorders (CD). Many patients diagnosed with CHI have other neurological or mental illnesses (primary headaches, vestibulopathies, anxiety and depressive disorders), which, unfortunately, are not diagnosed. Prevention of stroke, which is based on the correction of risk factors (smoking, alcohol abuse, low physical activity, and obesity), the treatment of hypertension, diabetes and other diseases is of major importance in the management of patients with CHI. Inhibitors of central acetyl cholinesterase and akatinol memantine showed efficacy in the management of significant vascular CD. The article discusses the issues of use of Divaza for the management of CHI, provides the results of DIAMANT multicentre observational study.
About the Author
V. A. Parfenov
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
References
1. Gusev EI, Bogolepova AN. Cognitive disorders in cerebrovascular diseases. Moscow: MEDPRESSINFORM, 2013. 180 p.
2. Parfenov VA, Zakharov VV, Preobrazhenskaya IS. Cognitive disorders. M., Remedium, 2014. 224 p.
3. Parfenov VA. Dyscirculatory encephalopathy and vascular cognitive disorders. M., IMA-PRESS, 2017. 128 p.
4. Cerebrovascular disease, cognitive impairment and dementia. Cerebrovascular disease and dementia. 2nd ed. Edited by O’Brien J, Ames D, Gustafson L, et al. London; N.Y.: Martin Dunitz, 2004.
5. Gorelick PB, Scuteri A, Black SE, et al. Vascular Contributions to Cognitive Impairment and Dementia: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke, 2011, 42: 2672-713.
6. Sachdev P, Kalaria R, O’Brien J, et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord, 2014, 28(3): 206-18.
7. Samorodskaya IV, Andreev EM, Zaratyants OV et al. Mortality rates for cerebrovascular diseases in patients older than 50 years over a 15-year period in Russia and the United States. Nevrologiya, Neyropsikhiatriya i Psihosomatika, 2017, 9 (1): 15-24.
8. Miche J-P. Is It Possible to Delay or Prevent Age-Related Cognitive Decline? Korean J Fam Med, 2016, 37(5): 263-6.
9. Andrieu S, Coley N, Lovestone S, et al. Prevention of sporadic Alzheimer’s disease: lessons learned from clinical trials and future directions. Lancet Neurol, 2015, 14: 926-44.
10. Yakhno NN, Levin OS, Damulin IV. Comparison of clinical and MRI data in discirculatory encephalopathy. Message 2: cognitive disorders. Nevrologicheskiy Zhurnal, 2001, 6 (3): 10-19.
11. Preobrazhenskaya IS, Yakhno N.N. Vascular cognitive impairment: clinical manifestations, diagnosis, treatment. Nevrologicheskiy Zhurnal, 2007, 12 (5): 45-50.
12. Яхно Н.Н., Захаров В.В., Локшина А.Б. и др. Деменции. Москва: Медпресс-информ, 2011. / Yakhno NN, Zakharov VV, Lokshina AB, et al. Dementia. Moscow: Medpress-inform, 2011.
13. Neverovskii DV, Sluchevskaya SF, Parfenov VA. Differential diagnosis of discirculatory encephalopathy in outpatient practice. 2013 Nevrologiya, Neyropsihiatriya i Psikhosomatika, 2013, 5 (2): 38-42.
14. Peng J, Lu F, Wang Z, et al. Excessive lowering of blood pressure is not beneficial for progression of brain white matter hyperintensive and cognitive impairment in elderly hypertensive patients: 4-year follow-up study. J Am Med Dir Assoc, 2014, 15: 904-10.
15. Spinelli C, de Caro MF, Schirosi G, et al. Impaired cognitive executive dysfunction in adult treated hypertensives with a confirmed diagnosis of poorly controlled blood pressure. Int J Med Sci, 2014, 11: 771-8.
16. Solomon A, Mangialasche F, Richard E, et al. Advances in the prevention of Alzheimer’s disease and dementia. J Intern Med, 2014, 275(3): 229-50.
17. European Stroke Organisation (ESO) Executive Committee, ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack. Cerebrovasc Dis, 2008, 25: 457-507.
18. Jacobs V, May HT, Bair TL, et al. Long-term population-based cerebral ischemic event and cognitive outcomes of direct oral anticoagulants compared with warfarin among longterm anticoagulated patients for atrial fibrillation. Am J Cardiol, 2016, 118(2): 210-14.
19. Shinohara M, Sato N, Shimamura M, et al. Possible modification of Alzheimer’s disease by statins in midlife: interactions with genetic and non-genetic risk factors. Front Aging Neurosci, 2014, 6: 71.
20. De Waard DD, Morris D, De Borst GJ, et al. Asymptomatic carotid artery stenosis: who should be screened, who should be treated and how should we treat them? J Cardiovasc Surg (Torino), 2017, 58(1): 3-12.
21. Carta MG, Pala AN, Finco G, et al. Depression and cerebrovascular disease: Could vortioxetine represent a valid treatment option. Clin Pract Epidemiol Ment Health, 2015, 11: 144-9.
22. Koenig AM, Butters MA. Cognition in late life depression treatment considerations. Curr Treat Options Psychiatry, 2014, 1(1): 1-14.
23. Herrmann N, Lanctot KL, Hogan DB. Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. Alzheimers Res Ther, 2013, 5(Suppl 1): S5.
24. Tanaeva KK, Dugina YuL, Kachaeva EV, Epstein OI. Prospects for the use of divaza in the pathogenetic therapy of chronic cerebral ischemia. Zhurnal Nevrologii i Psihiatrii Im. S.S. Korsakova, 2014, 114 (9): 94-8.
25. Ganina KK, Dugina YuL, Zhavbert ES, Ertuzun IA, Epshtein OI, Mukhin VN, Abdurasulova IN Antiamnestic effects of divaza and its components on the β-amyloid amnesia models in rats. Zhurnal Nevrologii i Psihiatrii Im. S.S. Korsakova, 2016, 116 (9): 69-74.
26. Parfenov VA, Kamchatnov PR, Vorobyova OV, Gustov AV, Glushkov KS, Doronina ОB. The multicenter study of the efficacy and safety of divas in asthenic and mild or moderate cognitive disorders in the elderly and senile. Zhurnal Nevrologii i Psihiatrii Im. S.S. Korsakova, 2017, 117 (9): 43-50.
27. World Health Organization, Alzheimer’s Disease International. Dementia: a public health priority [Internet] Geneva: World Health Organization, 2012.
Review
For citations:
Parfenov VA. Diagnosis and treatment of chronic cerebral ischemia. DIAMANT study results. Meditsinskiy sovet = Medical Council. 2018;(9):8-12. (In Russ.) https://doi.org/10.21518/2079-701X-2018-9-8-12
Views:
1594
Email this article 